The Stride implant, along with Blue Belt’s NavioPFS implantation system, use 3D visualization and computer navigation to guide hand-held instruments during bone resurfacing and knee implant surgeries.
Blue Belt won 510(k) clearance from the FDA in June 2013 for the Stride implant. The multi-year deal will see ART manufacture knee implant components "sufficient for the build-up of Blue Belt’s surgical kits as well as on-going replenishment," according to a press release.
“We are very pleased that Micron was selected as a primary supplier of implant components to Blue Belt. We think that the NavioPFS smart surgical instrument is an innovative technology which holds great potential for orthopedic surgeons. The Stride unicondylar knee system is optimized for Blue Belt’s NavioPFS platform,” ART president & CEO Salvatore Emma said in prepared remarks.
Fitchburg, Mass.-based Arrhythmia Research Technology closed a $500,000 private placement at the start of this year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.